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BACKGROUND: Molecularly targeted agents with anti-angiogenic activity, including bevacizumab, have demonstrated clinical activity in
patients with advanced/metastatic hepatocellular carcinoma (HCC). This multicentre phase II study involving patients from several
Asian countries sought to evaluate the safety and efficacy of bevacizumab plus capecitabine in this population.
METHODS: Histologically proven/clinically diagnosed advanced HCC patients received bevacizumab 7.5mgkg
–1 on day 1 and
capecitabine 800mgm
–2 twice daily on days 1–14 every 3 weeks as first-line therapy.
RESULTS: A total of 45 patients were enrolled; 44 (96%) had extrahepatic metastasis and/or major vessel invasion and 30 (67%) had
hepatitis B. No grade 3/4 haematological toxicity occurred. Treatment-related grade 3/4 non-haematological toxicities included
diarrhoea (n¼2, 4%), nausea/vomiting (n¼1, 2%), gastrointestinal bleeding (n¼4, 9%) and hand–foot syndrome (n¼4, 9%). The
overall response rate (RECIST) was 9% and the disease control rate was 52%. Overall, median progression-free survival (PFS) and
overall survival (OS) were 2.7 and 5.9 months, respectively. Median PFS and OS were 3.6 and 8.2 months, respectively, for Cancer of
the Liver Italian Programme (CLIP) score p3 patients, and 1.4 and 3.3 months, respectively, for CLIP score 4 patients.
CONCLUSION: The bevacizumab–capecitabine combination shows good tolerability and modest anti-tumour activity in patients with
advanced HCC.
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Primary liver cancer, which consists predominantly of hepato-
cellular cancer (HCC), is the fifth most common cancer worldwide
and the third most common cause of cancer mortality (El-Serag
and Rudolph, 2007). More than 80% of cases occur in East Asia
and sub-Saharan Africa, although the incidence is increasing in
parts of Europe (Capocaccia et al, 2007) and the United States
(El-Serag and Rudolph, 2007). Patients with locally advanced or
metastatic HCC face a dismal outcome. Conventional chemo-
therapy is rarely successful and often poorly tolerated (Palmer
et al, 2004; Zhu, 2006a). In the past, the median survival for these
patients diagnosed in Asia was typically 2–4 months with best
supportive care (Hsu et al, 2010).
Recently, sorafenib, a multikinase inhibitor with anti-angiogenic
activity (Wilhelm et al, 2004, 2006), demonstrated a survival benefit vs
best supportive care in patients with advanced HCC in two
randomised placebo-controlled trials, one conducted in Europe,
North America, South America and Australasia (the SHARP study,
Llovet et al, 2008b) and the other in the Asia-Pacific region (Cheng
et al,2 0 0 9 ) .B o t ht r i a l sr e p o r t e ds i m i l ar objective response rates (2–
3%) and disease control rates (35–43%); overall survival (OS) was
10.7 months in the SHARP trial (Llovet et al, 2008b) and 6.5 months
in the Asia-Pacific trial (Cheng et al, 2009). Although the survival
benefit conferred by sorafenib in advanced HCC is an encouraging
development, there is still a substantial unmet medical need for
effective treatment options with favourable safety profiles in this
difficult-to-treat population.
Hepatocellular carcinomas are known to be highly vascularised,
with elevated vascular endothelial growth factor (VEGF) and
microvessel density levels (Yamaguchi et al, 1998; Pang and Poon,
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s2006). The VEGF and VEGFR signalling pathways are the prime
targets for developing anti-angiogenic therapy as cancer thera-
peutics. Bevacizumab is an anti-VEGF antibody that targets
tumour angiogenesis and has proven benefit in many solid
tumours (Hurwitz et al, 2004; Miller et al, 2005; Sandler et al,
2006); bevacizumab has also been investigated in advanced HCC in
a phase II setting. As a single agent, bevacizumab had an objective
tumour response rate of 13% in patients with unresectable non-
metastatic HCC (Siegel et al, 2008). The combination of
bevacizumab with standard chemotherapy – a strategy that has
demonstrated clinical benefit in patients with colorectal, lung and
breast cancer (Hurwitz et al, 2004; Miller et al, 2005; Sandler et al,
2006) – has also been tested in patients with HCC. In phase II
studies, the combination of bevacizumab with gemcitabine–
oxaliplatin (GEMOX) (Zhu et al, 2006b) or capecitabine–
oxaliplatin (XELOX) (Sun et al, 2007) resulted in response rates
of up to 20%, although these regimens were associated with
significant treatment-related toxicity. To have a wider application,
bevacizumab combinations with a better therapeutic index need to
be developed.
Capecitabine, an oral fluoropyrimidine with a favourable safety
profile, has been widely used in various types of solid cancers
(Roche Products Limited, 2009). Theoretically, capecitabine may
have an advantage when treating patients with an abnormal liver
function. Indeed, Twelves et al (1999) demonstrated that mild to
moderate hepatic dysfunction has no clinically significant
influence on the pharmacokinetic parameters of capecitabine and
its metabolites. In a retrospective analysis, capecitabine mono-
therapy resulted in a response rate of 11% in patients with
advanced HCC (Patt et al, 2004).
The combination of bevacizumab with capecitabine, two drugs
that have previously demonstrated single-agent activity in patients
with advanced HCC, has not yet been evaluated in patients with
advanced HCC. The present phase II study was conducted at
multiple Asian centres to evaluate the tolerability and efficacy of
bevacizumab plus capecitabine in patients with advanced or
metastatic HCC.
PATIENTS AND METHODS
Patients
Patients aged X18 years were included if they had histologically
confirmed or clinically diagnosed HCC (typical imaging findings
plus a-fetoprotein X400ngml
–1); stage IV disease (American
Joint Committee on Cancer, 1998) that was inoperable and not
amendable by other locoregional therapies; Child–Pugh class A;
Karnofsky performance status X70%; X1 measurable lesion;
neutrophil count X2000 per ml; platelet count X150000 per ml;
alanine aminotransferase level p5 upper normal limit (UNL); or
bilirubin p1.2 UNL. Exclusion criteria included earlier radio-
therapy/systemic therapy for advanced HCC; central nervous
system metastases; previous HCC rupture; and clinically signifi-
cant cardiovascular disease. Patients with a history of gastro-
intestinal bleeding within 1 year or known oesophageal/gastric
varices were required to undergo gastroduodenoscopy to exclude
active bleeding and a high risk of bleeding.
The study conformed to the principles of the Declaration of
Helsinki and Good Clinical Practice Guidelines, with approval
obtained from each centre’s independent ethics committee.
Patients provided written informed consent.
Treatment
Patients received intravenous bevacizumab 7.5mgkg
–1 on day 1
and oral capecitabine 800mgm
–2twice daily on days 1–14 every 3
weeks. The dose of capecitabine was selected on the basis of
several observations indicating that capecitabine given in lower
doses demonstrated an improved therapeutic index (Sakamoto
et al, 2004; Hennessy et al, 2005). For example, in a Japanese
cohort of advanced colorectal cancer patients, capecitabine
at a dose of 828mgm
–2 twice daily resulted in an improved
toxicity profile without compromising its anti-tumour activities
(Sakamoto et al, 2004). Six treatment cycles were planned, but
patients maintaining a response or stable disease after six cycles
could continue treatment at the investigator’s discretion.
No dose reduction of bevacizumab was allowed, except for
patients with 410% change in body weight during the treatment
period. Bevacizumab was discontinued in patients with gastro-
intestinal perforation, arterial thrombotic toxicity, grade 3/4
haemorrhagic toxicity, symptomatic grade 4 thromboembolic
toxicity, hypertensive crisis or nephrotic syndrome. Bevacizumab
was withheld for grade 3 hypertension and repeated 24h
proteinuria 42g until these symptoms improved. Capecitabine
doses were reduced by 20% for patients who experienced a first
occurrence of a grade 3 haematological toxicity, a second
occurrence of grade 2 non-haematological toxicity or any
grade 3 non-haematological toxicity. Capecitabine doses were
reduced by 40% for a first occurrence of grade 4 haematological
toxicity, a second occurrence of grade 3 haematological
toxicity, any grade 4 non-haematological toxicity, a second
occurrence of grade 3 non-haematological toxicity or a third
occurrence of grade 2 non-haematological toxicity. Capecitabine
was discontinued after the occurrence of a second grade 4
haematological toxicity, a third grade 3 haematological toxicity, a
fourth grade 2 non-haematological toxicity, a third grade 3 non-
haematological toxicity or a second grade 4 non-haematological
toxicity.
Assessments
Tumour assessment according to the Response Evaluation Criteria
in Solid Tumors (RECIST) was performed every 6 weeks using
computed tomography/magnetic resonance imaging. Adverse
events (AEs) were graded using National Cancer Institute Common
Terminology Criteria for Adverse Events, version 3 (National
Cancer Institute, 2008).
Statistical analyses
The null hypothesis (H0) was that the overall response rate (ORR)
was p10%, that is, low activity. The alternative hypothesis (H1)
was that ORR was X25%, that is, encouraging activity. To
distinguish between an ORR of 10 and 25%, assuming a- and
b-error rates of 0.05 and 0.20, respectively, a sample size of 43
patients was required using Ensign’s three-stage design (Ensign
et al, 1994). Stage 1 enrolled nine patients and would stop if no
responses were confirmed. Stage 2 would enrol 25 patients
(including the nine patients from stage 1) and would stop if
pthree responses were confirmed. If sufficient responses were
observed in stages 1 and 2, the trial proceeded to stage 3, recruiting
45 patients in total.
The primary objective of this study was to evaluate the ORR for
capecitabine plus bevacizumab in patients with advanced/meta-
static HCC. ORR was assessed in the per-protocol population,
which excluded patients who did not have adequate baseline or X1
follow-up tumour assessment. Secondary objectives included
safety, disease control rate, progression-free survival (PFS) and
OS. Secondary analyses were performed on the intent-to-treat
population. The PFS and OS were analysed using Kaplan–Meier
plots and presented as median event times with 95% confidence
intervals (CIs).
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sRESULTS
Patients
Between May 2005 and August 2006, 45 Asian patients were
enrolled at eight centres in Taiwan, Singapore and Hong Kong.
Patients’ baseline characteristics are shown in Table 1. All patients
except one had extrahepatic metastases (n¼31) and/or major
hepatic vessel invasion (n¼25): thus 44 patients (98%) had
Barcelona Clinic Liver Cancer (BCLC) stage C cancer and one had
BCLC stage B disease. The most common disease sites were the
liver (91%), lung (47%) and lymph nodes (31%).
Patients received a median of three cycles (range 1–31 cycles) of
bevacizumab plus capecitabine: 38 patients (87%) completed two
cycles, 21 (47%) completed four cycles and 15 (33%) completed six
cycles. Among these 15 patients, seven continued study treatment
for between 10 and 31 cycles. The reasons for discontinuation
before six cycles were progressive disease in 25 patients, safety
concern in four patients (fulminant hepatitis, gastrointestinal
bleeding, hypoalbuminaemia and hyponatraemia, respectively),
and withdrawal of consent in one patient. The capecitabine dose
was reduced in five patients (elevated bilirubin, n¼1; hand–foot
syndrome, n¼2; grade 3 diarrhoea, n¼1; vomiting, n¼1). The
bevacizumab dose was delayed in three patients as a result of
capecitabine toxicity and adjusted in one patient because of weight
loss.
Efficacy
One patient with no follow-up tumour assessment was excluded
from the per-protocol population; 44 patients were therefore
evaluable for response. Four patients had a partial response and 19
had stable disease for an ORR of 9% and a disease control rate of
52% (95% CI: 36.7–67.5%; Table 2).
Serum alpha-fetoprotein (AFP) levels were serially monitored.
A total of 37 patients who had elevated baseline AFP were eligible
for AFP response. AFP response was 24% if defined by 20% decline
from baseline (Chan et al, 2009) or 13% if defined by 50% decline
(Chen et al, 2005; Vora et al, 2009).
After a median follow-up of 19.6 months, the median PFS was
2.7 months (95% CI: 1.5–4.1 months) and median OS was 5.9
months (95% CI: 4.1–9.7 months) in the intent-to-treat population
(Figure 1). The 1-year PFS rate was 20% (95% CI: 8–32%) and
1-year OS was 27% (95% CI: 14–40%). Correlations between
several baseline characteristics and PFS/OS were explored. Only
Cancer of the Liver Italian Programme (CLIP) score was
significantly correlated with outcome: median PFS was higher in
patients with CLIP scores p3 compared with those with a score of
4 (3.6 months (95% CI: 1.5–6.0 months) vs 1.4 months (95% CI:
1.2–3.3 months)), whereas median OS was 8.2 months (95% CI:
5.0–11.3 months) vs 3.3 months (95% CI: 2.5–5.2 months),
respectively.
Tolerability
All 45 patients were evaluable for tolerability. The combination of
bevacizumab plus capecitabine was generally well tolerated. Grade
3/4 AEs and laboratory abnormalities are shown in Table 3. In
total, 43 patients (96%) experienced X1 AEs; 25 patients (56%)
had AEs that were possibly related to treatment; and 26 patients
(58%) had AEs that were probably related to treatment. Treatment-
related grade 3/4 toxicities were diarrhoea (n¼2, 4%), nausea/
vomiting (n¼1, 4%), gastrointestinal bleeding (n¼4, 9%,
including three patients with oesophageal variceal bleeding),
hand–foot syndrome (n¼4, 9%), lower respiratory tract infection
(n¼1, 2%) and proteinuria (n¼1, 2%).
A total of 15 patients had serious AEs; most were gastro-
intestinal in nature (n¼9). Three patients withdrew early from the
study as a result of AEs. No deaths were attributed to the study
treatment.
DISCUSSION
Targeted therapy with anti-angiogenic activity has become the
mainstay of systemic therapy for advanced HCC (National
Table 2 Efficacy of bevacizumab plus capecitabine in patients with
hepatocellular carcinoma (n¼44)
Outcome Value
Overall response rate (95% CI), % 9.1 (2.5–21.7)
Complete response, n (%) 0 (0)
Partial response, n (%) 4 (9.1)
Stable disease, n (%) 19 (43)
Progressive disease, n (%) 21 (48)
Disease control rate (95% CI), % 52.3 (36.7–67.5)
Abbreviation: CI¼confidence interval.
Table 1 Patient characteristics at baseline (n¼45)
Characteristic Value
Sex, n (%)
Male 40 (89)
Female 5 (11)
Median age, years (range) 54 (23–75)
Karnofsky performance status, n (%)
90–100 36 (80)
80 9 (20)
Baseline a-fetoprotein, n (%)
X400ngml
–1 32 (71)
o400ngml
–1 13 (29)
AJCC stage,
a n (%)
IVa 16 (36)
IVb 29 (64)
BCLC stage, n( % )
B 1 (2)
C 44 (98)
CLIP score, n (%)
p2 18 (40)
3 16 (36)
4 11 (24)
Okuda score, n( % )
I 21 (47)
II 24 (53)
Site of extrahepatic metastases, n (%)
Lung 21 (47)
Lymph nodes 14 (31)
Prior curative surgery or locoregional therapy, n (%)
Yes 11 (24)
No 34 (76)
Virology of underlying liver disease, n (%)
HBV 30 (67)
HCV 8 (18)
Non-B+non-C 10 (22)
Abbreviations: BCLC¼Barcelona Clinic Liver Cancer; CLIP¼Cancer of the Liver
Italian Programme; HBV¼hepatitis B virus; HCV¼hepatitis C virus.
aAmerican Joint
Committee on Cancer (1998) staging system.
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sComprehensive Cancer Network, 2007). Previous studies have
shown that bevacizumab is also effective in this difficult-to-treat
indication (Zhu et al, 2006b; Sun et al, 2007; Siegel et al, 2008).
Further evidence of this activity has been demonstrated in this
study. However, the study did not meet the hypothesis that ORR
would be X25%, although ORR, combined with PFS and OS,
suggests activity for this combination. Retrospectively, it has been
recognised that ORR may not be an informative end point in
studies of targeted agents for advanced HCC (Llovet et al, 2008a).
At first glance, the efficacy results reported here are lower than
those previously reported in bevacizumab–chemotherapy combi-
nation trials (Zhu et al, 2006b; Sun et al, 2007). Nevertheless,
comparisons between studies of advanced HCC are complicated by
differences in recruitment criteria and study designs, as well as
by differences in baseline patient characteristics, in particular the
proportion of Asian patients in the studies. This is illustrated
by two recent sorafenib studies: the SHARP study, which enrolled
patients exclusively from Europe and North America (Llovet et al,
2008b), and the Asia-Pacific study, which enrolled patients
exclusively from China, Korea and Taiwan (Cheng et al, 2009).
Both studies used the same eligibility criteria and were conducted
in parallel; although clinical improvement was comparable in the
two studies, overall outcomes were much poorer in patients in the
Asia-Pacific study. Specifically, median OS was 4.2 and 6.5 months
for placebo- and sorafenib-treated patients in the Asia-Pacific
study, respectively, compared with 7.9 and 10.7 months in the
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Figure 1 Duration of progression-free survival (A) and overall survival (B) in patients treated with capecitabine and bevacizumab (n¼45).
Table 3 Adverse events in patients with hepatocellular carcinoma
treated with capecitabine plus bevacizumab (n¼45)
No. of patients (%)
Event All grades Grade 3 Grade 4
Adverse events
Hand–foot syndrome 15 (33) 4 (9) 0 (0)
Nausea 7 (16) 1 (2) 0 (0)
Vomiting 6 (13) 1 (2) 0 (0)
Diarrhoea 12 (27) 2 (4) 0 (0)
Gastrointestinal bleeding 4 (9) 2 (4) 2 (4)
Proteinuria 2 (4) 1 (2) 0 (0)
Lower respiratory tract infection 1 (2) 1 (2) 0 (0)
Fulminant hepatitis 1 (2) 0 (0) 1 (2)
Mucositis 5 (11) 0 (0) 0 (0)
Skin pigmentation 3 (7) 0 (0) 0 (0)
Laboratory values
Anaemia 12 (27) 2 (4) 2 (4)
Neutropenia 1 (2) 0 (0) 0 (0)
Thrombocytopenia 12 (27) 0 (0) 0 (0)
Increased hepatic transaminases
ALT 12 (27) 0 (0) 1 (2)
AST 20 (44) 6 (13) 1 (2)
Hyperbilirubinaemia 30 (67) 5 (11) 0 (0)
Abbreviations: ALT¼alanine aminotransferase; AST¼aspartate aminotransferase.
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bevacizumab with or without chemotherapy in advanced HCC
patients were all reported from North America (Zhu et al, 2006b;
Sun et al, 2007; Siegel et al, 2008). Taking the advanced HCC
patients enrolled in the Asia-Pacific study of sorafenib as a
reference group (Cheng et al, 2009), the efficacy outcomes of the
current combination are comparable with those of sorafenib.
The efficacy of the bevacizumab plus capecitabine combination is
also likely to have been influenced by the fact that this study
included a large proportion of poor-prognosis patients. Almost a
quarter of patients had a CLIP score of 4, which is associated with
poor prognosis (Farinati et al,2 0 0 0 ;G r i e c oet al, 2005; Collette et al,
2008). In a study of survival in patients undergoing palliative
treatment, those with CLIP scores of 2–3 had a median OS of 4.57
months, whereas those with CLIP scores of 4–6 had a median OS of
1.93 months (Collette et al, 2008). This pattern was also apparent in
the present analysis of survival: patients with a CLIP score p3h a da
median PFS of 3.6 months and an OS of 8.2 months compared with
1.4 months and 3.3 months, respectively, for patients with a CLIP
score of 4. These data suggest that CLIP score is an important
stratification factor for clinical trials in advanced HCC.
The combination of bevacizumab plus capecitabine was well
tolerated in this group of patients with advanced HCC. Grade 3/4
haematological toxicities were not observed and the rate of other
grade 3/4 toxicities was low. Gastrointestinal bleeding occurred in
four patients, three of whom had oesophageal variceal bleeding.
Mandatory gastroduodenoscopy was later incorporated into the
screening phase for this study. Other bevacizumab HCC studies
also adopted measures to exclude patients at high risk of bleeding
(Siegel et al, 2008; Thomas et al, 2009). For example, in the study
by Siegel et al (2008), the protocol was amended after a variceal
bleed that led to the death of one patient in the safety evaluation
phase; the amendment required subsequent patients who had
varices before or evidence of varices on computed tomography/
magnetic resonance imaging to undergo endoscopy within 4 weeks
of study entry (Siegel et al, 2008).
The favourable toxicity profile of our regimen, compared with
other combinations used in HCC, is primarily because of the low
toxicity of reduced-dose capecitabine. For comparison, the
combination of bevacizumab plus GEMOX was associated with
grade 3/4 neutropaenia and thrombocytopaenia in 42 and 9% of
patients, respectively (Zhu et al, 2006b). Bevacizumab plus XELOX
was associated with grade 3/4 neutropaenia and thrombocyto-
paenia in 6 and 12% of patients, respectively, and with grade 3/4
peripheral neuropathy in 12% of patients (Sun et al, 2007). More
stringent inclusion criteria adopted in our study, including higher
levels of baseline neutrophil and platelet, may also contribute to
the negligible haematological toxicity in our cohort.
The significance of adding capecitabine to bevacizumab in
advanced HCC patients could not be evaluated in the current
single-arm study. The single-agent response rate of bevacizumab,
as reported by Siegel et al (2008), was 13%, which was even higher
than that of our combination. However, the high response rate of
bevacizumab shown in that report could be associated with the
following facts: the study excluded patients with extrahepatic
metastases; it enrolled patients with different aetiological factors;
and used higher doses of bevacizumab in two-thirds of their
patients. Further studies are warranted to identify the optimal dose
of bevacizumab, as well as more effective combinations of
bevacizumab in HCC (Thomas et al, 2009).
In summary, the combination of bevacizumab plus capecitabine
shows good tolerability and modest anti-tumour activity in
patients with advanced or metastatic HCC. Randomised trials are
required to determine whether the combination of chemotherapy
and bevacizumab is superior to treatment with bevacizumab alone.
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